Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operati... ( DALLAS Jan. 30 -- Officials with Bay...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer

Date:1/30/2009

DALLAS, Jan. 30 /PRNewswire-USNewswire/ -- Officials with Baylor Health Care System announced today that Bernard Brigonnet will join the Baylor Research Institute (BRI) as vice president and chief operating officer, effective Feb. 1.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090130/DC65143)

Under his leadership, the institute will further pursue the development of its unique research technologies in areas such as immunology, transplantation, metabolic disease, cardiovascular disease and colon cancer, to name a few.

In addition, Brigonnet will oversee the institute's more than $40 million a year budget which has grown in just ten short years to become a major clinical research program.

"Baylor is increasingly becoming a leader in medical research and we hope to license our advanced technologies in the marketplace to reach even more patients who need them," says Michael Ramsay, M.D., president, Baylor Research Institute. "Mr. Brigonnet has a tremendous vision of where BRI can take the Baylor Health Care System and we are very excited to have someone of his caliber take us to the next level."

A native of France, Brigonnet has more than 30 years of experience in the biotechnology and pharmaceutical industries where he has served in a senior leadership capacity for a number of international organizations.

Most recently as CEO of Medicen Paris Region, he helped create one of the largest collaborations of research institutes, pharmaceutical and biotechnology companies as well as public and private universities following an initiative by the French government to support world-competitive clusters for innovation in life sciences. Prior to that, he served as president and CEO of Serono France S.A., a leader in the development and manufacturing of biopharmaceutical treatments.

SOURCE Baylor Health Care System
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
2. Home Oxygen Community Applauds Senator Bernard Sanders for Joining Bi-Partisan Effort to Formally Oppose Proposed Cuts to Medicares Home Oxygen Benefit
3. Bernard A. Krooks From the Special Needs Alliance to Talk Tax Strategies for Individuals With Disabilities Tomorrow on Good Morning America NOW
4. Vikings Wide Receiver Bernard Berrian Pledges Up to $10,000 to Second Harvest Heartland; Challenges the Community and Fellow Vikings to Help Feed the Hungry This Holiday Season
5. Zimmer Holdings Names Betsy Bernard to Board of Directors
6. Richard Greco Joins Mediware Board
7. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
8. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
9. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
10. Nick Childs Joins Grey New York as Director of Content Development
11. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2 Health News:Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges' 2 Health News:Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3 Health News:Second-line CML drugs evoke faster response than front-line therapy 2

[1] Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients [0] Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges'[0] Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 [0] Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 [0] Second-line CML drugs evoke faster response than front-line therapy

ADA Urges President Bush Not to Veto Critical Appropriations Bill AUA releases new guidelines on non-muscle invasive bladder cancer Warning for women who binge drink Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees Physics provides new insights on cataract formation

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 4 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 1 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 2 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 1 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 1 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 3

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program [0] Van Andel Institute Cuts Ribbon on $178 Million Expansion

Other Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 2 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 3 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 4

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting

Medicine Products:

Allsport Ankle Ortho II QualCare™ Compression Ankle Support VenaFlow® System SCD EXPRESS Compression System

Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operati...( DALLAS Jan. 30 -- Officials with Bay...),Health